

**Magnesium polyethylene glycol: a novel therapeutic agent for
traumatic brain injury**

Diana Sabiiti Busingye MBChB

Discipline of Anatomy and Pathology, School of Medical Sciences

University of Adelaide

December 2014

A thesis submitted in partial fulfillment of the requirements for the degree of

Master of Medical Science

Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Date

Diana Busingye Sabiiti

Dedication

This thesis is dedicated to my mother Tophers Sabiiti, who has always believed in me, encouraged and supported me in every way possible.

Publications, presentations and awards

The following articles have been published or accepted for publication or presentation during the period of my Masters candidature, and sections of these articles have been included in the present thesis.

Book Chapter

Diana S. Busingye, Renée J. Turner and Robert Vink (2015) Emerging therapies in traumatic brain injury, in *Critical Care in Traumatic Brain Injury* (DX Cifu, BC Eapen, eds), Future Science Group, London (in press).

Presentation Abstracts

Sabiiti-Busingye D, Turner R, Vink R (2014) Combined magnesium polyethylene glycol as a novel therapy in traumatic brain injury. Aust. Neurosci. Soc. Abstr. P62.

Sabiiti-Busingye D (2014) Magnesium polyethylene glycol: a novel therapy for traumatic brain injury? Proc. Aust. Soc. Med. Res.

Award

Sir Grafton Elliot-Smith award for best student poster presentation, the Australian Neuroscience Society Conference, Adelaide, January 2014.

ACKNOWLEDGEMENTS

This journey wouldn't have been possible without the help and support of so many wonderful people. I would like to acknowledge my mother for paying my international student tuition and my living expenses.

To my Principle supervisor, Prof. Robert Vink. I am grateful for the opportunity to undertake research in your lab. You have been a great mentor throughout my candidature. Thank you for sharing your immense knowledge, proofreading my thesis and being patient with a beginner like me. I will always remember your hospitality and thank you for inviting me to celebrate my first Christmas and New years' in Australia with your family.

To my co-supervisor Dr Renee Turner, thank you for the constant reminders on upcoming deadlines throughout my candidature especially my with the completion of my core component. Thank you for the reading books at the start of my candidature.

Anna and Liz, thanks for your help with Evan's blue and immunohistochemistry. Liz, thank you for the yummy cupcakes you made for my first birthday in Australia.

Jim Manavis, I was always amazed at your cheerfulness and positivity every single day! Thanks for teaching me the immunohistochemistry staining technique.

To my mother, I am forever grateful for your love, encouragement and financial support. Your faith in me was incredible even when everything seemed insurmountable. David, it was always a pleasure chatting to you.

To my husband Joseph thank you for always being there through thick and thin, standing by me, supporting me, encouraging me, helping with my poster presentation and formatting my thesis.

You are my rock, best friend and biggest cheerleader.

Last but not least, to my beautiful daughter Tara. Coming home to your smile, cuddles and kisses after a long day meant the whole world to me.

ABBREVIATIONS

APP	Amyloid Precursor Protein
ATP	Adenosine Triphosphate
AQP	Aquaporin
BBB	Blood Brain Barrier
Ca ²⁺	Calcium
cAMP	Cyclic adenosine monophosphate
DAB	Diaminobenzidine tetrahydrochloride
CGRP	Calcitonin-gene Related Peptide
CNS	Central Nervous System
CPP	Cerebral Perfusion Pressure
CSF	Cerebrospinal fluid
DAI	Diffuse Axonal Injury
EB	Evans Blue
GCS	Glasgow Coma Scale
H&E	Haematoxylin and Eosin

ICP	Intracranial Pressure
IV	Intravenous
Mg ²⁺	Magnesium
NHS	Normal Horse Serum
NMDA	N-methyl-D-aspartate
NO	Nitric Oxide
PBS	Phosphate Buffered Solution
rpm	Revolutions per minute
SD	Standard Deviation
SEM	Standard Error of Measurement
SP	Substance P
SPC	Streptavidin Peroxidase Conjugate
TBI	Traumatic Brain Injury

TABLE OF CONTENTS

PUBLICATIONS, PRESENTATIONS AND AWARDS	6
ACKNOWLEDGEMENTS	7
ABBREVIATIONS	10
TABLE OF TABLES	16
LIST OF FIGURES	17
ABSTRACT	19
CHAPTER 1	21
1. INTRODUCTION	22
1.1 TRAUMATIC BRAIN INJURY.	22
1.1.1 <i>Overview</i>	22
1.1.2 <i>Epidemiology</i>	24
1.2 PRIMARY AND SECONDARY INJURY.....	24
1.2.1 <i>Primary TBI</i>	24
1.2.2 <i>Secondary Injury</i>	25
1.3 OEDEMA AND THE BLOOD BRAIN BARRIER	30
1.3.1 <i>The Blood Brain Barrier</i>	31
1.3.2 <i>Cerebral oedema</i>	36
1.3.3 <i>Management of oedema</i>	40
1.4 SUBSTANCE P	44
1.4.1 <i>Synthesis</i>	45
1.5 MAGNESIUM	47

1.5.1 <i>Distribution of Magnesium in the human body</i>	48
1.6 MODELS OF INJURY	52
CHAPTER 2	60
2. METHODS.....	61
2.1 ANIMAL CARE	61
2.1.1 <i>Ethics</i>	61
2.1.2 <i>General</i>	61
2.2 EXPERIMENTAL PROCEDURES	61
2.2.1 <i>Anesthesia</i>	61
2.2.2 <i>Induction of TBI</i>	62
2.2.3 <i>Perfusion</i>	64
2.3 DRUG TREATMENTS	64
2.4 FUNCTIONAL TESTS	64
2.4.1 <i>Motor function</i>	64
2.4.2 <i>Cognitive outcome</i>	67
2.5 OEDEMA MEASUREMENT	68
2.5.1 <i>Brain water content</i>	68
2.6 BLOOD BRAIN BARRIER PERMEABILITY.....	69
2.6.1 <i>Quantitative Evaluation</i>	69
2.7 TISSUE PROCESSING	70
2.7.1 <i>Blocking and Embedding</i>	70
2.7.2 <i>Microtome sectioning</i>	70
2.8 HISTOLOGY AND IMMUNOHISTOCHEMISTRY	71
2.8.1 <i>Haematoxylin and Eosin staining</i>	71

2.8.2 Substance P Immunohistochemistry	71
2.8.3 Albumin	72
2.9 STATISTICAL ANALYSIS	73
CHAPTER 3	74
3. RESULTS	75
3.1 BLOOD BRAIN BARRIER PERMEABILITY AFTER TBI	75
3.1.1 Experimental outline	75
3.1.2 BBB PERMEABILITY AFTER TBI	76
3.1.2.1 Determination of BBB permeability to EB	76
3.1.2.2 BBB permeability by albumin immunoreactivity	77
3.2 MAGNESIUM AND OEDEMA, SUBSTANCE P RELEASE AND CELL INJURY	81
3.2.1 EXPERIMENTAL OUTLINE	81
3.2.2 Oedema, substance P and neuronal cell injury after TBI	82
3.2.2.3 HAEMATOXYLIN AND EOSIN STAINING	87
3.4 FUNCTIONAL OUTCOME	93
3.4.1 EXPERIMENTAL DESIGN	93
3.4.2.1 ROTAROD	94
CHAPTER 4	98
4. DISCUSSION	99
4.1 BLOOD BRAIN BARRIER PERMEABILITY AND ALBUMIN IMMUNOHISTOCHEMISTRY	99
4.2 OEDEMA AND SUBSTANCE P RELEASE	102
4.3 HISTOLOGICAL H&E ANALYSIS	105
4.4 FUNCTIONAL OUTCOME	109

4.5 CONCLUSION	112
CHAPTER 5	113
5. REFERENCES	114

TABLE OF TABLES

Table 2.1	Relationship between rotational speed and time in seconds on the rotarod device.....	65
-----------	--	----

LIST OF FIGURES

Figure 1.1	Structure of the normal blood brain barrier.....	31
Figure 1.2	Models of injury.....	53
Figure 2.1	Mamarou’s model of traumatic brain injury.....	63
Figure 2.2	10mm stainless steel disc on rat’s skull.....	63
Figure 2.3	Rotarod device.....	66
Figure 2.4	Object recognition test.....	68
Figure 2.5	Halogen moisture analyzer.....	69
Figure 3.1	BBB permeability with Evan’s blue dye after TBI.....	77
Figure 3.2	Cortical albumin immunoreactivity 5hrs following TBI (A) sham animals (B) vehicle treated animals (C) PEG treated animals (D) MgCl ₂ treated animals (E) Mg PEG treated animals.....	79
Figure 3.3	Oedema at 5hrs following severe diffuse TBI.....	83
Figure 3.4	SP immunoreactivity at 5hrs following diffuse TBI (A) sham animals (B) vehicle treated animals (PEG) treated animals (D) MgCl ₂ treated animals (E) Mg PEG treated animals.....	85
Figure 3.5	Cortical hematoxylin and eosin staining at 3days following diffuse	

	TBI (A) shams (B) vehicle treated animals (C) PEG treated animals (D) MgCl ₂ treated animals (E) Mg PEG treated animals.....	88
Figure 3.6	Haematoxylin and eosin staining in area CA2 of the hippocampus 3days following TBI (A) sham animals (B) vehicle treated animals (C) PEG treated animals (D) MgCl ₂ treated animals (E) Mg PEG treated animals.....	90
Figure 3.7	Haematoxylin and eosin staining in area CA2 of the hippocampus 7days following diffuse TBI in rats (A) shams (B) Vehicle treated animals (C) animals treated with 0.1x MgCl ₂ (D) animals treated with 0.1x Mg PEG.....	92
Figure 3.8	Motor function as assessed by the rotarod device over 7days.....	95
Figure 3.9	Object recognition test results following TBI.....	97
Figure 4.2	Substance P resulting in neurogenic inflammation after TBI.....	106

ABSTRACT

A number of experimental studies have shown that decline in intracellular free magnesium is a ubiquitous feature of traumatic brain injury (TBI), and that restoration of magnesium homeostasis improves both cognitive and motor outcome. However, a recent large, randomized clinical trial of magnesium in TBI failed, in part because of poor central penetration of the magnesium salt. Subsequent experimental studies in spinal cord injury have shown that magnesium penetration into the CNS can be facilitated if the magnesium salt is administered in a solution containing polyethylene glycol (PEG), a polymer that facilitates transport across the blood brain barrier and throughout the extracellular space. Accordingly, the current study characterised the therapeutic potential of high and low dose magnesium chloride, either alone or in combination with PEG, on oedema, blood brain barrier permeability, brain histology and functional outcome following moderate diffuse TBI in rats.

Adult male Sprague Dawley rats (350-380 g) exposed to moderate diffuse TBI induced using the impact acceleration injury model, were administered intravenous magnesium polyethylene glycol (Mg PEG) (254 μ moles/kg $MgCl_2$ in 1g/kg PEG), the same concentration (optimal dose) of $MgCl_2$ or PEG alone, or equal volume vehicle at 30 min postinjury. A separate group of surgically prepared animals were neither injured or treated and served as shams. All animals were subsequently assessed for oedema, blood barrier permeability, brain histology and functional outcome for up to 1 week after trauma. Administration of either Mg PEG or optimal dose $MgCl_2$ alone significantly improved all outcome parameters compared to vehicle treated or PEG treated controls with no significant difference between the magnesium treatment groups. Indeed,

magnesium treatment restored all parameters to sham levels. However, intravenous administration of one-tenth the magnesium concentration (25.4 $\mu\text{moles/kg}$; low dose) had no beneficial effect on any of the outcome parameters whereas one-tenth the magnesium concentration in PEG (25.4 $\mu\text{moles/kg}$ MgCl_2 in 1g/kg PEG) had the same beneficial effects as optimal dose MgCl_2 . We conclude that PEG facilitates movement of the magnesium salt across the blood brain barrier following TBI and that the combination of low dose magnesium in PEG significantly attenuates oedema, blood brain barrier permeability and improves motor and cognitive outcome following TBI.